Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases
Authors:
- 11 June 2019
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 68 (7) , 1187-1194
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2017
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International ConsensusJournal of Bone and Mineral Research, 2014
- Treg and CTLA-4: Two intertwining pathways to immune toleranceJournal of Autoimmunity, 2013
- Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signallingNature, 2011
- Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastasesJournal of Cellular Physiology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Pathologic fractures correlate with reduced survival in patients with malignant bone diseaseCancer, 2007
- Regulation of cancer cell migration and bone metastasis by RANKLNature, 2006
- A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell functionNature, 1997